Compare AbCellera Biologics Inc (ABCL) vs Chevron Corp (CVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Chevron Corp — how do they compare? AbCellera Biologics Inc trades at $7.29 (market cap $2.35B), while Chevron Corp trades at $175.81 (market cap $346.56B). The key difference: Chevron Corp is far larger — about 147.5× AbCellera Biologics Inc's market cap, and Chevron Corp pays a 4.09% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CVX | |
|---|---|---|
Market Cap | $2.35B | $346.56B |
Sector | Health | Energy |
52-Week High | $8.12 | $211.14 |
52-Week Low | $2.78 | $146.72 |
Enterprise Value | $1.99B | $386.66B |
Volume | — | 9,807,834 |
Dividend Yield | — | 4.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Chevron (CVX) trades at $168.1, down 0.66% on the day, amid a broader technical bearish signal. The stock shows mixed fundamentals with declining revenue and net income over recent years, though it has consistently beaten earnings expectations. A strong $1.78 dividend is scheduled for payment in June 2026. Wall Street sentiment remains predominantly bullish, with a consensus price target of $209 representing significant upside, countering the current technical weakness.
The investment case balances a high analyst buy rating and attractive dividend against fundamental profit margin compression and exposure to volatile oil prices. Key risks include execution of major projects like the $13.8B Argentina investment and geopolitical tensions affecting supply chains. The stock's current price sits near immediate technical support at $167.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
